253 related articles for article (PubMed ID: 15205450)
41. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries.
Ralevic V; Kendall DA; Randall MD; Zygmunt PM; Movahed P; Högestätt ED
Br J Pharmacol; 2000 Aug; 130(7):1483-8. PubMed ID: 10928948
[TBL] [Abstract][Full Text] [Related]
42. Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain.
Yoshihara S; Morimoto H; Ohori M; Yamada Y; Abe T; Arisaka O
Pharmacology; 2006; 76(4):157-62. PubMed ID: 16446560
[TBL] [Abstract][Full Text] [Related]
43. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
Rawls SM; Cabassa J; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
[TBL] [Abstract][Full Text] [Related]
44. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation.
Makwana R; Molleman A; Parsons ME
Br J Pharmacol; 2010 Jun; 160(3):615-26. PubMed ID: 20590566
[TBL] [Abstract][Full Text] [Related]
45. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.
Gouldson P; Calandra B; Legoux P; Kernéis A; Rinaldi-Carmona M; Barth F; Le Fur G; Ferrara P; Shire D
Eur J Pharmacol; 2000 Jul; 401(1):17-25. PubMed ID: 10915832
[TBL] [Abstract][Full Text] [Related]
46. The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide.
O'Sullivan SE; Kendall DA; Randall MD
Br J Pharmacol; 2005 Jun; 145(4):514-26. PubMed ID: 15821751
[TBL] [Abstract][Full Text] [Related]
47. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Stewart JL; McMahon LR
J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
[TBL] [Abstract][Full Text] [Related]
48. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
49. Cannabinoid activation of recombinant and endogenous vanilloid receptors.
Ralevic V; Kendall DA; Jerman JC; Middlemiss DN; Smart D
Eur J Pharmacol; 2001 Jul; 424(3):211-9. PubMed ID: 11672565
[TBL] [Abstract][Full Text] [Related]
50. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
51. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
52. Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor.
Raborn ES; Cabral GA
J Pharmacol Exp Ther; 2010 Apr; 333(1):319-27. PubMed ID: 20089805
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
[TBL] [Abstract][Full Text] [Related]
54. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro.
Kojima S; Sugiura T; Waku K; Kamikawa Y
Eur J Pharmacol; 2002 May; 444(3):203-7. PubMed ID: 12063081
[TBL] [Abstract][Full Text] [Related]
55. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats.
Mendiguren A; Pineda J
Eur J Pharmacol; 2006 Mar; 534(1-3):83-8. PubMed ID: 16483566
[TBL] [Abstract][Full Text] [Related]
56. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.
Mato S; Pazos A; Valdizán EM
Eur J Pharmacol; 2002 May; 443(1-3):43-6. PubMed ID: 12044790
[TBL] [Abstract][Full Text] [Related]
57. Analysis of the effects of cannabinoids on synaptic transmission between basket and Purkinje cells in the cerebellar cortex of the rat.
Szabo B; Than M; Thorn D; Wallmichrath I
J Pharmacol Exp Ther; 2004 Sep; 310(3):915-25. PubMed ID: 15123767
[TBL] [Abstract][Full Text] [Related]
58. Diuretic effects of cannabinoids.
Paronis CA; Thakur GA; Bajaj S; Nikas SP; Vemuri VK; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Jan; 344(1):8-14. PubMed ID: 23019138
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory effects of SR141716A on G-protein activation in rat brain.
Sim-Selley LJ; Brunk LK; Selley DE
Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
